Treatment after failure: the problem of "non-responders"

被引:39
|
作者
Huang, JQ [1 ]
Hunt, RH [1 ]
机构
[1] McMaster Univ, Med Ctr, Div Gastroenterol, Hamilton, ON L8N 3Z5, Canada
关键词
D O I
10.1136/gut.45.2008.i40
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Although the currently most effective treatment regimens cure about 90% of infections, 10% of patients remain Helicobacter pylori positive. Several factors contribute to treatment failure. These include patient compliance, bacterial resistance to antibiotics, and treatment related issues. Treatment failure leads to the development of bacterial resistance to metronidazole and clarithromycin. Retreatment can be undertaken after considering several different strategies: to repeat the same regimen with full doses of medications and a longer treatment duration, or to choose different regimens to avoid the antibiotic previously used, or to switch to proton pump inhibitor (PPI) based quadruple therapy or ranitidine bismuth citrate (RBC) based triple therapy. In principle, full doses and longer treatment durations are advisable. As retreatment is always difficult, choosing the best available first line treatment regimen is sill the best "rescue" treatment.
引用
收藏
页码:I40 / I44
页数:5
相关论文
共 50 条
  • [41] DIFFERENTIAL EXPRESSION OF SEMINAL PLASMA PROTEINS IN RESPONDERS AND NON-RESPONDERS TO VARICOCELE TREATMENT
    Bitsoev, Timur
    Chagovets, Vitaliy
    Shatylko, Taras
    Tokareva, Alisa
    Gamidov, Safar
    Starodubtseva, Natalia
    Popova, Alina
    Frankevich, Vladimir
    JOURNAL OF UROLOGY, 2022, 207 (05): : E636 - E636
  • [42] Super-Responders and Non-Responders to CGRP Monoclonal Antibodies in the Treatment of Migraine
    Shadbehr, N.
    Lee, M.
    Patel, P.
    George, N.
    Hanidu, I
    Tariq, H.
    Bucklan, J. N.
    Kriegler, J. S.
    Mays, M.
    Ahmed, Z.
    HEADACHE, 2020, 60 : 25 - 26
  • [43] Determining responders and non-responders to fish consumption
    Potter, T.
    Sneddon, A.
    Zock, P.
    Alssema, M.
    Wanders, A.
    Zandstra, L.
    Thies, F.
    de Roos, B.
    PROCEEDINGS OF THE NUTRITION SOCIETY, 2019, 78 (OCE2) : E56 - E56
  • [44] Prevalence of 'responders' and 'non-responders' to antiplatelet drugs
    Achaval, M. G. Gonzalez
    Ghione, S.
    Hadad, M.
    Gomez, S.
    Del Val, L. A.
    Balestrini, C.
    CIRCULATION, 2008, 118 (12) : E350 - E351
  • [45] A Comparison of Responders and Non-responders Is Lacking Reply
    Senska, Gotz
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2016, 113 (25): : 431 - 432
  • [46] Options for non-responders to monotherapy
    Bacon, B
    NON-RESPONDING HEPATITIS C PATIENT: OPTIONS AND VARIABLES, 2000, (70): : 5 - 13
  • [47] What to do with non-responders
    Villanueva, C
    Aracil, Q
    Balanzó, J
    PORTAL HYPERTENSION IN THE 21ST CENTURY, 2004, : 337 - 348
  • [48] Early Responders, Late Responders, and Non-responders: The Principal-Agent Problem in Board Oversight of Nonprofit CEOs
    Tillotson, Amanda Rowe
    Tropman, John
    HUMAN SERVICE ORGANIZATIONS MANAGEMENT LEADERSHIP & GOVERNANCE, 2014, 38 (04) : 374 - 393
  • [49] TAILORING THERAPY IN ACUTE HEART FAILURE: CAN BIOMARKERS DISTINGUISH RESPONDERS FROM NON-RESPONDERS?
    Liu, Licette
    Valente, Mattia A. E.
    Postmus, Douwe
    O'Connor, Christopher
    Metra, Marco
    Ponikowski, Piotr
    Teerlink, John
    Cotter, Gad
    Davison, Beth
    Cleland, John
    Givertz, Michael
    Bloomfield, Daniel
    van Veldhuisen, Dirk
    Hillege, Hans
    van der Meer, Peter
    Voors, Adriaan
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A1013 - A1013
  • [50] DIFFERENCES IN INFLAMMATORY AND COMPLEMENT PROTEINS BETWEEN RESPONDERS AND NON-RESPONDERS AFTER GASTRIC BYPASS
    Sima, E.
    Sundbom, M.
    OBESITY SURGERY, 2016, 26 : S270 - S271